Insight

Jun 30, 2024, 14:51

Sergio Cifuentes: Phase 2 study on neoadjuvant nivolumab + ipilimumab in dMMR colon cancer

Sergio Cifuentes, Cancer Research Project Manager at CENEIT México, shared a post on X about a recent paper by Myriam Chalabi et al. titled “Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer” published in The New England Journal of Medicine:

Sergio Cifuentes commented on X sharing this paper:

“Phase 2 study on neoadjuvant nivolumab + ipilimumab in dMMR colon cancer: 98% timely surgery, 95% major pathological response, 0 recurrences in 26 months.”

Source: Sergio Cifuentes/X

Anja Van Lent Brechtje Grotenhuis cancer Cecile Grootscholten CENEIT México dMMR dMMR colon cancer Eduard Hendriks Emile Voest Geerard Beets Inge Huibregtse ipilimumab Jacobus Burger John Haanen José van den Berg June Rogers Colon Cancer Research Fund. Koert Kuhlmann Lodewyk Wessels Monique Van Leerdam Myriam Chalabi Neoadjuvant nivolumab plus ipilimumab Nikè Büller nivolumab OncoDaily Oncology Pedro Batista Tan Petur Snaebjornsson Regina Beets-Tan Sara Balduzzi Sergio Cifuentes Simone Dokter Steven Oosterling Tjeerd Aukema Ton Schumacher Yara Verschoor

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage